US 9,175,094 B2 · Monoclonal antibody

Abstract

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

Claims36

Dependent claims

A method for treating a disease or disorder which is caused by or associated with amyloid or amyloid-like proteins, comprising administering to a subject in need thereof:

(a) a monoclonal antibody, or an active fragment thereof, which is produced by hybridoma cell line FG1F9E4, deposited on May 25, 2007 and given deposit number DSM ACC2845;
(b) a monoclonal antibody, or an active fragment thereof, which is produced by hybridoma cell line FK2A6A6, deposited on May 25, 2007 and given deposit number DSM ACC2846;
or
(c) an anti-amyloid beta antibody, or active fragment thereof, wherein
i. complementarity determining region (CDR) 1 of the light chain variable region has the amino acid sequence of SEQ ID NO:11;
ii. CDR2 of the light chain variable region has the amino acid sequence of SEQ ID NO:12;
iii. CDR3 of the light chain variable region has the amino acid sequence of SEQ ID NO:13;
iv. CDR1 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:14;
v. CDR2 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:15;
and
vi. CDR3 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:16.

8 more elements

A method for reducing the plaque load in the brain of a subject suffering from a disease or condition associated with an increased plaque load in the brain comprising administering to the subject a therapeutically effective amount of:

(a) a monoclonal antibody, or an active fragment thereof, which is produced by hybridoma cell line FG1F9E4, deposited on May 25, 2007 and given deposit number DSM ACC2845;
(b) a monoclonal antibody, or an active fragment thereof, which is produced by hybridoma cell line FK2A6A6, deposited on May 25, 2007 and given deposit number DSM ACC2846;
or
(c)
an anti-amyloid beta antibody, or active fragment thereof, wherein
i. CDR1 of the light chain variable region has the amino acid sequence of SEQ ID NO:11;
ii. CDR2 of the light chain variable region has the amino acid sequence of SEQ ID NO:12;
iii. CDR3 of the light chain variable region has the amino acid sequence of SEQ ID NO:13;
iv. CDR1 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:14;
v. CDR2 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:15;
and
vi. CDR3 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:16.

9 more elements

A method for decreasing the total amount of soluble Aβ in the brain of a subject suffering from a disease or condition associated with increased concentrations of soluble Aβ in the brain comprising administering to the subject a therapeutically effective amount of:

(a) a monoclonal antibody, or an active fragment thereof, which is produced by hybridoma cell line FG1F9E4, deposited on May 25, 2007 and given deposit number DSM ACC2845;
(b) a monoclonal antibody, or an active fragment thereof, which is produced by hybridoma cell line FK2A6A6, deposited on May 25, 2007 and given deposit number DSM ACC2846;
or
(c)
an anti-amyloid beta antibody, or active fragment thereof, wherein
i. CDR1 of the light chain variable region has the amino acid sequence of SEQ ID NO:11;
ii. CDR2 of the light chain variable region has the amino acid sequence of SEQ ID NO:12;
iii. CDR3 of the light chain variable region has the amino acid sequence of SEQ ID NO:13;
iv. CDR1 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:14;
v. CDR2 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:15;
and
vi. CDR3 of the heavy chain variable region has the amino acid sequence of SEQ ID NO:16.

9 more elements

Dependencies are inferred from the claim text.

Monoclonal antibody

Life of this patent

Monoclonal antibody

Life of this patent

Abstract

Claims36